Eliane Sardh

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(4):675-686

Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study.

Mantel Ä; Vassiliou D; Lissing M; Stephansson O; Wahlin S; Sardh E
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(2):286-299

Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals.

Lissing M; Vassiliou D; Floderus Y; Harper P; Yan J; Hagström H; Sardh E; Wahlin S
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):824-836

Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.

Lissing M; Vassiliou D; Floderus Y; Harper P; Bottai M; Kotopouli M; Hagström H; Sardh E; Wahlin S
Article: LIVER INTERNATIONAL. 2022;42(1):161-172

Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E; ENVISION Investigators
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):81-94

Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies.

Vassiliou D; Sardh E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(5):1250-1260

A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.

Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2021;100(9):1712-1721

Treatment with assisted reproduction technologies in women with acute hepatic porphyria.

Vassiliou D; Lindén Hirschberg A; Sardh E
Article: GENOME MEDICINE. 2021;13(1):40

Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients.

Stranneheim H; Lagerstedt-Robinson K; Magnusson M; Kvarnung M; Nilsson D; Lesko N; Engvall M; Anderlid B-M; Arnell H; Johansson CB; Barbaro M; Björck E; Bruhn H; Eisfeldt J; Freyer C; Grigelioniene G; Gustavsson P; Hammarsjö A; Hellström-Pigg M; Iwarsson E; Jemt A; Laaksonen M; Enoksson SL; Malmgren H; Naess K; Nordenskjöld M; Oscarson M; Pettersson M; Rasi C; Rosenbaum A; Sahlin E; Sardh E; Stödberg T; Tesi B; Tham E; Thonberg H; Töhönen V; von Döbeln U; Vassiliou D; Vonlanthen S; Wikström A-C; Wincent J; Winqvist O; Wredenberg A; Ygberg S; Zetterström RH; Marits P; Soller MJ; Nordgren A; Wirta V; Lindstrand A; Wedell A
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(24):2289-2301

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.

Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang J-D; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L; ENVISION Investigators
Article: HEPATOLOGY. 2020;71(5):1546-1558

EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.

Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stölzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach J-C; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2019;380(6):549-558

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.

Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
Article: JOURNAL OF INTERNAL MEDICINE. 2018;284(1):78-91

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.

Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec J-Y; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach J-C; Puy H; Peoc'h K; Manceau H; Gouya L
Article: JOURNAL OF PROTEOMICS. 2015;127(Pt B):377-385

Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.

Serrano-Mendioroz I; Sampedro A; Mora MI; Mauleón I; Segura V; Enríquez de Salamanca R; Harper P; Sardh E; Corrales FJ; Fontanellas A
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2013;36(6):1063-1071

High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.

Sardh E; Wahlin S; Björnstedt M; Harper P; Andersson DEH
Article: PLOS ONE. 2012;7(3):e32978

Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.

Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
Article: TRANSPLANT INTERNATIONAL. 2010;23(6):e18-e21

Combined liver and kidney transplantation in acute intermittent porphyria.

Wahlin S; Harper P; Sardh E; Andersson C; Andersson DE; Ericzon B-G
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2009;20(2):201-207

Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.

Sardh E; Harper P; Andersson DEH; Floderus Y
Article: CELLULAR AND MOLECULAR BIOLOGY. 2009;55(1):66-71

Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.

Sardh E; Andersson DEH; Henrichson A; Harper P
Article: CLINICAL PHARMACOKINETICS. 2007;46(4):335-349

Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.

Sardh E; Rejkjaer L; Andersson DEH; Harper P
Article: CLINICAL CHEMISTRY. 2006;52(4):701-707

Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.

Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DEH; Harper P
Article: INFLAMMATION. 2002;26(6):291-296

Modulation of plasma levels of soluble adhesion molecules and nitric oxide in healthy volunteers by exposure to swine dust.

Kölbeck K-G; Sardh E; Gyllenhammar H; Palmberg L; Larsson K K; Palmblad J
Visa fler

Alla övriga publikationer

Editorial comment: CANCERS. 2023;15(3):795

Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947.

Lissing M; Vassiliou D; Harper P; Sardh E; Wahlin S
Review: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. 2022;16(9):879-894

Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.

Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli M-J; Sweetser MT; Petrides PE
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;112(1):24

Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported.

Bins S; Sardh E; Langendonk JG
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(5):593-610

RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.

Sardh E; Harper P
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;290(4):928-930

Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase.

Vassiliou D; Sardh E
Other: CLINICAL CASE REPORTS. 2020;8(12):2483-2487

Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report.

Vassiliou D; Lempessi C; Harper P; Sardh E
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2020;383(20):1989-1990

Givosiran for Acute Intermittent Porphyria. Reply.

Balwani M; Sardh E; Gouya L
Review: EXPERT OPINION ON ORPHAN DRUGS. 2014;2(4):349-368

Management of acute intermittent porphyria

Harper P; Sardh E

Anställningar

Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för klinisk forskning o utbildning, Södersjukhuset, Karolinska Institutet, 2008
Läkarexamen, Karolinska Institutet, 1995

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI